These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16097842)

  • 1. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
    Martikainen JA; Kivioja A; Hallinen T; Vihinen P
    Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
    Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
    Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup economic analysis for glioblastoma in a health resource-limited setting.
    Wu B; Miao Y; Bai Y; Ye M; Xu Y; Chen H; Shen J; Qiu Y
    PLoS One; 2012; 7(4):e34588. PubMed ID: 22511951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
    Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
    J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
    [No Abstract]   [Full Text] [Related]  

  • 7. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
    Uyl-de Groot CA; Stupp R; van der Bent M
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
    Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
    Osoba D; Brada M; Yung WK; Prados M
    J Clin Oncol; 2000 Apr; 18(7):1481-91. PubMed ID: 10735896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
    Messali A; Hay JW; Villacorta R
    Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
    Yung WK; Albright RE; Olson J; Fredericks R; Fink K; Prados MD; Brada M; Spence A; Hohl RJ; Shapiro W; Glantz M; Greenberg H; Selker RG; Vick NA; Rampling R; Friedman H; Phillips P; Bruner J; Yue N; Osoba D; Zaknoen S; Levin VA
    Br J Cancer; 2000 Sep; 83(5):588-93. PubMed ID: 10944597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade glioma in children and adolescents: a single-center experience.
    Yazici G; Zorlu F; Cengiz M; Ozyigit G; Eren G; Yüce D; Varan A; Akyuz C; Akalan N; Gurkaynak M
    Childs Nerv Syst; 2016 Feb; 32(2):291-7. PubMed ID: 26679932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
    Wasserfallen JB; Ostermann S; Pica A; Mirimanoff RO; Leyvraz S; Villemure JG; Stupp R
    Cancer; 2004 Nov; 101(9):2098-105. PubMed ID: 15389472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
    Roussakow SV
    BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
    Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
    J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
    Wasserfallen JB; Ostermann S; Leyvraz S; Stupp R
    Neuro Oncol; 2005 Apr; 7(2):189-95. PubMed ID: 15831237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
    Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
    Mabasa VH; Taylor SC
    J Oncol Pharm Pract; 2006 Jun; 12(2):105-11. PubMed ID: 16984749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.